我們已在上線! 進一步了解
RCOR

Renovacor, Inc.

已下市

RCOR已於2022年11月30日下市。

 

關於: Renovacor Inc is a preclinical stage gene therapy company developing a pipeline of innovative and proprietary AAV-based gene therapies for BAG3 gene mutation-associated diseases in areas of high unmet medical need. Its therapeutic focus is on cardiovascular disease, with a lead program in BAG3 mutation-associated dilated cardiomyopathy.

員工: 19

新聞

正面
中性
負面
市場情緒 3個月
正面 0%
中性 0%
負面 0%

我們尚未收到任何關於RCOR的最新新聞文章。

價格圖表採用Lightweight Charts™實作